Literature DB >> 529024

Time-dependent kinetics. V: Time course of drug levels during enzyme induction (one-compartment model).

R H Levy, M S Dumain, J L Cook.   

Abstract

Equations were derived to describe the time course of drug levels during auto- and heteroinduction under a variety of input conditions. These equations were based on a pharmacokinetic theory of induction which assumes that metabolic clearance increases exponentially to a maximum value and that the rate of this increase is governed by the degradation rate constant of the induced enzyme (k'). Closed form solutions could be obtained only for intravenous single-dose (case I) and multiple-dose (case IV) administration. For each of the other cases, constant-rate intravenous infusion (case III), oral single-dose administration (case II), and multiple-dose administration (case V), an exact solution (not closed form) and an approximation (closed form) were derived. Two sets of equations were derived for each of the five cases to take into consideration the possibility of a latency term (lambda). Plots of drug amount X (or concentration C) vs. time (t) were constructed. In case I, a log X vs. t plot was convex, the slope increasing with time. In case II, X increased, reached a peak, and decayed as in case I. In case III (lambda greater than 5 ln 2V/Q) C reached a preinduction steady state before decreasing to a lower (induced) steady state. The behavior of C vs. t for cases IV and V was similar to that for case III. Determination of parameters was attempted in case III. Nonlinear least-square fitting of generated data with 3-9% error yielded reasonable estimates of k'.

Mesh:

Substances:

Year:  1979        PMID: 529024     DOI: 10.1007/BF01061209

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  6 in total

1.  Time-dependent kinetics IV: Pharmacokinetic theory of enzyme induction.

Authors:  R H Levy; A A Lai; M S Dumain
Journal:  J Pharm Sci       Date:  1979-03       Impact factor: 3.534

2.  Pharmacokinetic description of drug interactions by enzyme induction: carbamazepine-clonazepam in monkeys.

Authors:  A A Lai; R H Levy
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

3.  Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine.

Authors:  W H Pitlick; R H Levy; A S Tropin; J R Green
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

4.  Influence of turnover rates on the responses of enzymes to cortisone.

Authors:  C M Berlin; R T Schimke
Journal:  Mol Pharmacol       Date:  1965-09       Impact factor: 4.436

5.  Time-dependent kinetics I: Exponential autoinduction of carbamazepine in monkeys.

Authors:  W H Pitlick; R H Levy
Journal:  J Pharm Sci       Date:  1977-05       Impact factor: 3.534

6.  Time-course of interaction between carbamazepine and clonazepam in normal man.

Authors:  A A Lai; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

  6 in total
  6 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

3.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

4.  A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.

Authors:  Toufigh Gordi; Rujia Xie; Nguyen V Huong; Dinh X Huong; Mats O Karlsson; Michael Ashton
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

5.  Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.

Authors:  Ryuta Asaumi; Ken-Ichi Nunoya; Yoshiyuki Yamaura; Kunal S Taskar; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-06

6.  Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.

Authors:  Ryuta Asaumi; Karsten Menzel; Wooin Lee; Ken-Ichi Nunoya; Haruo Imawaka; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.